On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -4.68% from the last session, before settling in for the closing price of $11.97. Price fluctuations for NTLA have ranged from $11.61 to $34.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.09% over the past five years. Company’s average yearly earnings per share was noted 1.96% at the time writing. With a float of $100.10 million, this company’s outstanding shares have now reached $101.80 million.
Let’s look at the performance matrix of the company that is accounted for 526 employees. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 1.71%, while institutional ownership is 92.38%. The most recent insider transaction that took place on Oct 02 ’24, was worth 38,248. In this transaction VP, Chief Accounting Officer of this company sold 2,012 shares at a rate of $19.01, taking the stock ownership to the 47,012 shares. Before that another transaction happened on Jul 01 ’24, when Company’s EVP, Chief Technical Officer sold 405 for $22.93, making the entire transaction worth $9,287. This insider now owns 71,470 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.00% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 6.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.34 in the next quarter and is forecasted to reach -5.49 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 1.87 million, a positive change from its year-to-date volume of 1.79 million. As of the previous 9 days, the stock’s Stochastic %D was 14.23%. Additionally, its Average True Range was 0.80.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 0.47%, which indicates a significant decrease from 1.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.28% in the past 14 days, which was lower than the 67.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.87, while its 200-day Moving Average is $21.18. Nevertheless, the first resistance level for the watch stands at $11.72 in the near term. At $12.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.22. If the price goes on to break the first support level at $11.22, it is likely to go to the next support level at $11.04. Assuming the price breaks the second support level, the third support level stands at $10.72.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 101,849K shares outstanding in the company with a market cap of 1.15 billion. Presently, the company’s annual sales total 36,280 K according to its annual income of -481,190 K. Last quarter, the company’s sales amounted to 9,110 K and its income totaled -135,710 K.
